A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients

This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).

Start Date30 Mar 2017

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with DPX-E7

100 Translational Medicine associated with DPX-E7

100 Patents (Medical) associated with DPX-E7

Literatures (Medical) associated with DPX-E7

07 Mar 2013·ISRN Oncology

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration

Article

Author: Quinton, Tara ; Blackman, Rachelle ; Karkada, Mohan ; Mansour, Marc

A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune responses. Given the relative poor efficacy associated with current cancer vaccines, a novel vaccine platform called DepoVaxTM (DPX) was developed. C3 tumor-challenged mice were immunized with HPV-E7 peptide in DPX- or conventional-emulsion- (CE-) based vaccine. While control mice showed marked increase in Treg/MDSCs in spleen and blood, in mice treated with DPX-E7 the levels remained similar to tumor-free naive mice. Such differences were also seen within the tumor. Antigen-specific IL10-secreting CD4/CD8 T cells and TGF-β+CD8+ T cell frequencies were increased significantly in CE-treated and control mice in contrast to DPX-E7-immunized mice. Analysis of tumor-infiltrating cells revealed higher frequency of suppressor cells in untreated controls than in DPX-E7 group while the converse was true for tumor-infiltrating CD8 T cells. Immunization of tumor-bearing HLA-A2 transgenic mice with human vaccine DPX-0907, a peptide-based vaccine for breast/ovarian/prostate cancers, showed efficient induction of immune response to cancer peptides despite the presence of suppressor cells. Thus, this study provides the rationale for using DPX-based cancer vaccines in immune-suppressed cancer patients, to induce effective anticancer immunity.

100 Deals associated with DPX-E7

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HPV16 positive Oropharyngeal Cancer	Phase 2	US	Dana-Farber Cancer Institute, Inc.	30 Mar 2017
Human Papillomavirus-Related Anal Squamous Cell Carcinoma	Phase 2	US	Dana-Farber Cancer Institute, Inc.	30 Mar 2017
Anus Neoplasms	Phase 2	-	Immunovaccine Technologies, Inc.	-
Head and Neck Neoplasms	Phase 2	-	Immunovaccine Technologies, Inc.	-
Uterine Cervical Cancer	Phase 2	-	Immunovaccine Technologies, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02865135 (CTgov)	Phase 1/2	HPV16 positive Oropharyngeal Cancer \| Uterine Cervical Cancer \| Head and Neck Neoplasms \| Anus Neoplasms \| Human Papillomavirus-Related Anal Squamous Cell Carcinoma	11	cyclophosphamide+DPX-E7 vaccine (DPX-E7 + Cyclophosphamide [Phase Ib Cohort])	hnoxzuedax(lmepkeadkh) = ummwazszts rmeblgaryy (iolgsnwiji, xeekmklikl - zgisenegzy) View more	-	11 Jan 2024
				cyclophosphamide+DPX-E7 vaccine (DPX-E7 + Cyclophosphamide [Phase II Cohort 1])	apnzcyilvj(hrpkcmpuwq) = pyaqhkxyez qhrkkwynyg (vbdugcaazj, jbumccrnxj - hvrzcfsppr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis